Durable Responses at ≥ 12 Months With Zola-cel in Severe Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Translational Findings From the Full Phase 1 Breakfree-1 Cohort (ACR Convergence 2026) - Oct 16, 2026 - Abstract #LB04; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; No abstract available
Clinical • Late-breaking abstract • P1 data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
|
|
Emily Littlejohn, DO, MPH
|